HIGHLIGHTS
- who: Daniel Lu and colleagues from the Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V Z , CanadaDepartment of Interdisciplinary Oncology, University of British Columbia, Vancouver, BC V Z , Canada have published the paper: MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis, in the Journal: Cancers 2022, 1378 of 21/Dec/2021
- what: The authors show that MET exon 14-skipping mutations specifically enhance signaling through the RAS/MAPK pathway, providing a potential avenue of combinatorial therapy to enhance patient survival. This study is aimed at facilitating the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.